Global Urothelial Carcinoma Treatment Market Highlights Over 2022 - 2031
The global urothelial carcinoma treatment market is estimated to garner a sizeable revenue by growing at a robust CAGR over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the increasing number of cases of bladder cancer, and growing popularity of targeted therapies across the globe. According to the World Cancer Research Fund, bladder cancer is the most commonly occurring cancer in men and 17th most cancer among women, with almost 550,000 new cases around the world in 2018.
Along with these, workers of pharmaceutical, textile and rubber industries are at greater risk of developing urothelial cancer owing to their direct exposure to chemicals, such as arsenics and arylamies. This in turn is expected to be a crucial factor raising the demand for the treatment in the forthcoming years. Furthermore, growing consumption of tobacco, and adoption of sedentary lifestyle practices are projected to offer ample growth opportunities to the market in the near future.
The market is segmented by treatment into chemotherapy, radiotherapy, and immunotherapy, out of which, the chemotherapy segment is anticipated to hold the largest share in the global urothelial carcinoma treatment market. This can be accounted to the fact that chemotherapy is one of the most common therapeutics to stop or slow down the growth of urothelial cancer cells. Apart from this, increase in the number of chemotherapy product launches and approvals for urothelial caner is also predicted to boost the growth of the market segment in the future. Additionally, on the basis of end user, the hospitals segment is assessed to grab the largest share during the forecast period ascribing to the large number of patient admissions, and presence of advanced medical equipment for treating complicated medical conditions in a hospital facility. CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Urothelial Carcinoma Treatment Market Regional Synopsis
Regionally, the global urothelial carcinoma treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the increasing occurrence of urothelial cancer, and growing number of smokers in the region. Moreover, the market in North America is expected to acquire the largest share during the forecast period, which can be credited to the rising healthcare expenditure, and surge in the adoption of novel cancer treatments in the region. As per the Centers for Medicare & Medicaid Services (CMS), the U.S. health care spending grew 9.7 percent in 2020, reaching USD 4.1 trillion or USD 12,530 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 19.7 percent. In addition, strong footprint of prominent market players is also projected to fuel the market growth in the region in the coming years.
The global urothelial carcinoma treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global urothelial carcinoma treatment market includes the following segments:
By Cancer Type
By End User
Top Featured Companies Dominating the Market
FREQUENTLY ASKED QUESTIONS
The major factors driving market growth are increasing number of cases of bladder cancer, and growing popularity of targeted therapies globally.
The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022-2031.
The major players in the market are Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Dendreon Pharmaceuticals LLC, Sanofi SA, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by cancer type, treatment, end user, and by region.
The chemotherapy segment is anticipated to hold largest market size and is estimated grow at a notable CAGR over the forecast period and display significant growth opportunities.
High cost of urothelial carcinoma therapy instruments is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities for market growth owing to the increasing occurrence of urothelial cancer, and growing number of smokers in the region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization